This inventor holds 1 USPTO granted patent. Top assignees: Beckman Research Institute, City of Hope, British Columbia Cancer Agency, Hospital Clinic De Barcelona. Active years: 2023.
Company Filing History:
1 out of 692 
1 out of 3 
1 out of 26 
Years Active: 2023
Title: German Ott: Innovator in Lymphoma Treatment
Introduction
German Ott is a notable inventor based in Munich, Germany. He has made significant contributions to the field of oncology, particularly in the diagnosis and treatment of lymphoma. His innovative approach has the potential to improve patient outcomes through more precise treatment methods.
Latest Patents
German Ott holds a patent for a method for determining lymphoma type and providing treatment. This invention provides a method for distinguishing between lymphoma types based on gene expression measurements. Specifically, it distinguishes between Primary Mediastinal B-cell Lymphoma (PMBCL) and Diffuse Large B-cell Lymphoma (DLBCL) based on gene expression signatures. Furthermore, it can differentiate between subtypes of DLBCL, allowing for tailored treatment strategies.
Career Highlights
Throughout his career, German Ott has worked with prestigious organizations such as the National Institutes of Health, a component of the US Department of Health & Human Services, and the British Columbia Cancer Agency. His work in these institutions has contributed to advancements in cancer research and treatment methodologies.
Collaborations
German Ott has collaborated with esteemed colleagues, including Louis M. Staudt and Christian Steidl. These partnerships have fostered a collaborative environment that enhances research and innovation in the field of lymphoma treatment.
Conclusion
German Ott's contributions to the field of oncology, particularly through his patented methods for lymphoma diagnosis and treatment, highlight his role as an innovator. His work continues to influence the landscape of cancer treatment, paving the way for more effective therapies.